Verona Pharma Future Growth
Future criteria checks 5/6
Verona Pharma is forecast to grow earnings and revenue by 54.3% and 37.7% per annum respectively while EPS is expected to grow by 52.6% per annum.
Key information
54.3%
Earnings growth rate
52.6%
EPS growth rate
| Pharmaceuticals earnings growth | 14.7% |
| Revenue growth rate | 37.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 30 Apr 2025 |
Recent future growth updates
Recent updates
This Just In: Analysts Are Boosting Their Verona Pharma plc (NASDAQ:VRNA) Outlook for This Year
May 01
Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Apr 12Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Mar 13New Forecasts: Here's What Analysts Think The Future Holds For Verona Pharma plc (NASDAQ:VRNA)
Mar 08Analysts Are Upgrading Verona Pharma plc (NASDAQ:VRNA) After Its Latest Results
Mar 02Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited
Jan 08Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Jan 07Verona Pharma: In COPD, There's A Corner With Their Name On It
Nov 27Verona Pharma: A Post FDA Approval Analysis
Sep 10Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Aug 10Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Jun 20Verona Pharma: Key Inflection Point Directly Ahead
May 23Verona Pharma: A Few Points From The Bull And Bear Case
Feb 15Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Jan 19Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Sep 13Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Aug 19Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Aug 09Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
Feb 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 1,035 | 416 | 418 | 227 | 6 |
| 12/31/2026 | 728 | 241 | 228 | 136 | 9 |
| 12/31/2025 | 407 | 21 | 49 | 1 | 10 |
| 3/31/2025 | 119 | -164 | -121 | -120 | N/A |
| 12/31/2024 | 42 | -173 | -123 | -122 | N/A |
| 9/30/2024 | 6 | -154 | -104 | -104 | N/A |
| 6/30/2024 | N/A | -125 | -54 | -54 | N/A |
| 3/31/2024 | N/A | -63 | -58 | -58 | N/A |
| 12/31/2023 | N/A | -54 | -50 | -50 | N/A |
| 9/30/2023 | 0 | -51 | -48 | -48 | N/A |
| 6/30/2023 | 0 | -52 | -53 | -53 | N/A |
| 3/31/2023 | 0 | -61 | -51 | -51 | N/A |
| 12/31/2022 | 0 | -69 | -60 | -60 | N/A |
| 9/30/2022 | N/A | -82 | -69 | -69 | N/A |
| 6/30/2022 | 40 | -55 | -29 | -29 | N/A |
| 3/31/2022 | 40 | -59 | -29 | -29 | N/A |
| 12/31/2021 | 40 | -56 | -33 | -33 | N/A |
| 9/30/2021 | 40 | -57 | -35 | -35 | N/A |
| 6/30/2021 | N/A | -87 | -68 | -68 | N/A |
| 3/31/2021 | N/A | -74 | -50 | -50 | N/A |
| 12/31/2020 | N/A | -65 | -45 | -45 | N/A |
| 9/30/2020 | N/A | -50 | -38 | -38 | N/A |
| 6/30/2020 | N/A | -43 | N/A | N/A | N/A |
| 3/31/2020 | N/A | -46 | -44 | -44 | N/A |
| 12/31/2019 | N/A | -41 | -43 | -43 | N/A |
| 9/30/2019 | N/A | -35 | -38 | -38 | N/A |
| 6/30/2019 | N/A | -25 | N/A | N/A | N/A |
| 3/31/2019 | N/A | -13 | -29 | -28 | N/A |
| 12/31/2018 | N/A | -25 | N/A | -23 | N/A |
| 9/30/2018 | N/A | -30 | N/A | -23 | N/A |
| 6/30/2018 | N/A | -40 | N/A | -33 | N/A |
| 3/31/2018 | N/A | -47 | N/A | -33 | N/A |
| 12/31/2017 | N/A | -28 | N/A | -28 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -24 | N/A |
| 6/30/2017 | N/A | -11 | N/A | -15 | N/A |
| 3/31/2017 | N/A | -8 | N/A | -10 | N/A |
| 12/31/2016 | N/A | -6 | N/A | -7 | N/A |
| 9/30/2016 | N/A | -8 | N/A | -6 | N/A |
| 6/30/2016 | N/A | -7 | N/A | -6 | N/A |
| 3/31/2016 | N/A | -9 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2015 | N/A | -10 | N/A | -9 | N/A |
| 6/30/2015 | N/A | -8 | N/A | -9 | N/A |
| 3/31/2015 | N/A | -6 | N/A | -7 | N/A |
| 12/31/2014 | N/A | -4 | N/A | -6 | N/A |
| 9/30/2014 | N/A | -5 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VRNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).
Earnings vs Market: VRNA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VRNA is expected to become profitable in the next 3 years.
Revenue vs Market: VRNA's revenue (37.7% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: VRNA's revenue (37.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VRNA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 22:59 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verona Pharma plc is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | Berenberg |
| Thomas Shrader | BTIG |
| Edward Nash | Canaccord Genuity |